Tags

Type your tag names separated by a space and hit enter

Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case series.
Lasers Med Sci. 2019 Feb; 34(1):93-98.LM

Abstract

Various lasers have been used for the treatment of erythematotelangiectatic rosacea (ETR), facial erythema (FE), and facial telangiectasias (FT). The assessment of the treatments of all of these conditions with a 577-nm pro-yellow laser has not been reported yet. The aim of this work was to assess the efficacy and safety of the 577-nm pro-yellow laser in ETR, FE, and FT. Forty patients suffering from ETR, FE, and FT (25 female and 15 male) were enrolled in this study. All of the patients were treated with 577-nm pro-yellow laser (QuadroStarPRO YELLOW® Asclepion Laser Technologies, Germany) at 4-week intervals, for one to four sessions. The assessment of the treatment was made based on the digital photographs and the percentage of fading of the erythema and telangiectasias in the lesions. Significant clinical improvement (80-100%) was observed in the first or second sessions of the treatment in FE and ETR patients and in second and fourth sessions of the treatment in FT patients. The treatment was very well tolerated. No side effect was observed except for a few patients who had mild to moderate erythema fading away in 12-24 h. This case series has shown that the pro-yellow laser is a very effective, safe, and well-tolerated treatment for ETR, FE, and FT.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kapicioglu Y
Department of Dermatology, Turgut Ozal Medical Center, Inonu University Faculty Of Medicine, Malatya, Turkey.
Sarac G
Department of Dermatology, Turgut Ozal Medical Center, Inonu University Faculty Of Medicine, Malatya, Turkey. gulbaharsarac@gmail.com.
Cenk H
Department of Dermatology, Malatya Training and Research Hospital, Malatya, Turkey.

MeSH

AdolescentAdultErythemaFaceFemaleHumansLasersMaleMiddle AgedRosaceaTelangiectasisTreatment OutcomeYoung Adult

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30097757

Citation

Kapicioglu, Yelda, et al. "Treatment of Erythematotelangiectatic Rosacea, Facial Erythema, and Facial Telangiectasia With a 577-nm Pro-yellow Laser: a Case Series." Lasers in Medical Science, vol. 34, no. 1, 2019, pp. 93-98.
Kapicioglu Y, Sarac G, Cenk H. Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case series. Lasers Med Sci. 2019;34(1):93-98.
Kapicioglu, Y., Sarac, G., & Cenk, H. (2019). Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case series. Lasers in Medical Science, 34(1), 93-98. https://doi.org/10.1007/s10103-018-2606-6
Kapicioglu Y, Sarac G, Cenk H. Treatment of Erythematotelangiectatic Rosacea, Facial Erythema, and Facial Telangiectasia With a 577-nm Pro-yellow Laser: a Case Series. Lasers Med Sci. 2019;34(1):93-98. PubMed PMID: 30097757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case series. AU - Kapicioglu,Yelda, AU - Sarac,Gulbahar, AU - Cenk,Hulya, Y1 - 2018/08/10/ PY - 2018/04/16/received PY - 2018/07/31/accepted PY - 2018/8/12/pubmed PY - 2019/2/26/medline PY - 2018/8/12/entrez KW - Facial erythema KW - Laser treatment KW - Pro-yellow laser KW - Treatment of rosacea SP - 93 EP - 98 JF - Lasers in medical science JO - Lasers Med Sci VL - 34 IS - 1 N2 - Various lasers have been used for the treatment of erythematotelangiectatic rosacea (ETR), facial erythema (FE), and facial telangiectasias (FT). The assessment of the treatments of all of these conditions with a 577-nm pro-yellow laser has not been reported yet. The aim of this work was to assess the efficacy and safety of the 577-nm pro-yellow laser in ETR, FE, and FT. Forty patients suffering from ETR, FE, and FT (25 female and 15 male) were enrolled in this study. All of the patients were treated with 577-nm pro-yellow laser (QuadroStarPRO YELLOW® Asclepion Laser Technologies, Germany) at 4-week intervals, for one to four sessions. The assessment of the treatment was made based on the digital photographs and the percentage of fading of the erythema and telangiectasias in the lesions. Significant clinical improvement (80-100%) was observed in the first or second sessions of the treatment in FE and ETR patients and in second and fourth sessions of the treatment in FT patients. The treatment was very well tolerated. No side effect was observed except for a few patients who had mild to moderate erythema fading away in 12-24 h. This case series has shown that the pro-yellow laser is a very effective, safe, and well-tolerated treatment for ETR, FE, and FT. SN - 1435-604X UR - https://www.unboundmedicine.com/medline/citation/30097757/Treatment_of_erythematotelangiectatic_rosacea_facial_erythema_and_facial_telangiectasia_with_a_577_nm_pro_yellow_laser:_a_case_series_ DB - PRIME DP - Unbound Medicine ER -